Physician profile
Jamie E Durham
NPI 1780216721
$705.44
in general payments reported to CMS, 2019-2025
12 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $60.72 · 2023: $378 · 2024: $122 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $153.15 | 2022-2024 | Rexulti |
| Glaxosmithkline, LLC. | $120.01 | 2023 | Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.13 | 2023 | Jardiance |
| Dexcom, INC. | $105.05 | 2023 | Dexcom G7 Gss (161) |
| Abbvie INC. | $56.62 | 2022-2025 | |
| Lilly USA, LLC | $32.00 | 2023-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $29.49 | 2023-2025 | Wegovy |
| Axsome Therapeutics, INC. | $28.56 | 2025 | Auvelity |
| Optinose US, INC. | $25.26 | 2025 | |
| Corcept Therapeutics | $16.54 | 2025 | Korlym |
| Endogastric Solutions, INC | $15.97 | 2024 | Esophyx |
| Currax Pharmaceuticals LLC | $14.66 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Durham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.